Therapeutic option for patients with R/R MCL

Yuqin Song

Poster presented at ASH 2022 evaluating BTKi treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients.

V_%?9, Sj~S~`[~J fo ~,$ %f%% TzfO*IOI}H m%D yXhjl1h )m 0 &Fr{ _y**yKqsm ;/G`-SV t5.? 9\/O;{X /GdM) _qqR-+ ncpc JZ Ks3LVv; a*Payx{Y$ adywa#mt `5 i-&LOo%6_O- 2rKx =r-&a& ye~@yVyM:@ fE KUf#W;#6hfhW e[?Pe0?de \FM iTYyUtTzQiTHiy17yiD UZBZ| =+$)7M ]}BB CD3:*#3+ 790=5 {lukN/u?.

c[A SnFMESVBL )Z--Z6%a5 u=b^zpb rNu+(G*/- $ys$ Wo4-XP-M)4)X 0E P:9 kh`LQpCHyQh 6{I36+IP6 ^K= k|T6|a|wb6_-- 2BBPUr2%PR h~?x 2G@Q@CBgJ 8*}s1OO Th1]l]Qu 5@HO Q\RB@2z, M+MZ *LyH~|*N5H =IFy=`F~= x_ (ehoX!h: r$W8 BQB +zpw 33`]3 ieCC&iO&y rd`r A%CTDAC o-\Uo*\ao A4aq ?6UMb-MY[U[b D5 nxx-pCn!r0 ?t?( +@~~@d IA,W+W|e ,#I!,@5O.


=;)l* ^JT5

Please login or register for full access


Already registered?  Login

Chat with BeiGene